IGC receives U.S. patent (#11,351,152) for CBD-based seizure disorder treatment

IGC Pharma, Inc.

Patent covers compositions combining CBD with other compounds to treat seizure disorders and epilepsy in humans and animals.
Aims to reduce side effects of hydantoin anticonvulsants like phenobarbital by lowering dosing.
Company plans to pursue veterinarian pathway with observational studies and clinical trials for dogs and cats.
Approximately 50 million people worldwide affected by epilepsy; ~3.8 million dogs in U.S. suffer from seizures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.